Expanded Access Study of Convalescent Plasma to Treat People with COVID-19 Infection

Share
Print

Full Title

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 (COVID)

Purpose

People who recover from COVID-19 do so, at least in part, because their blood contains substances called antibodies that fight the coronavirus that causes the illness. For some other diseases caused by respiratory viruses, giving people the liquid portion of blood (called plasma) obtained from those who have recovered from the virus leads to more rapid improvement of the disease. This plasma is called “convalescent plasma.”

Doctors believe that patients who have COVID-19 may recover more quickly if they receive plasma from those who have recovered from COVID-19, because it may have the ability to fight the virus that causes this infection. The purpose of this study is to assess the feasibility of collecting convalescent plasma from donors and also to assess the safety of infusing this convalescent plasma into patients with active COVID-19 disease. Patients will receive an infusion of convalescent plasma that is compatible with their blood type.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be hospitalized with severe COVID-19 infection or COVID-19 infection that has the potential to become severe or life-threatening.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Esperanza Papadopoulos at 646-608-3755.

Protocol

20-144

Disease Status

Newly Diagnosed & Relapsed/Refractory

Co-Investigators